You are here: Home > Index of tables and graphics
List of data elements by category
Tables
General population survey (GPS) tables
Studies of youth and the schools population (EYE) tables
Studies of the problematic drug use population (PDU) tables
Studies of drug users in prison (DUP) tables
Drug related infectious diseases (INF) tables
Drug-related deaths (DRD) tables
Drug law offences (DLO) tables
Demand for treatment for drug use (TDI) tables
Methadone substitution and needle and syringe programmes (NSP) tables
Drug availability and drug markets: seizures data (SZR) tables
Drug availability and drug markets: prices and purity information (PPP) tables
Figures
General population survey (GPS) figures
Studies of youth and the schools population (EYE) figures
Studies of the problematic drug use population (PDU) figures
Studies of drug users in prison (DUP) figures
Drug related infectious diseases (INF) figures
Drug-related deaths (DRD) figures
Drug law offences (DLO) figures
Demand for treatment for drug use (TDI) figures
Methadone substitution and needle and syringe (NSP) figures
Drug availability and drug markets: prices and purity information (PPP) figures
General population survey (GPS) tables
Table GPS-0. Nationwide surveys among the general population: bibliographic references
Table GPS-1 part (i) Lifetime prevalence all adults (percentage)
Table GPS-1 part (ii) Survey methods
Table GPS-2. Lifetime prevalence of drug use among young adults (15 to 34 years old) in nationwide surveys among the general population
Table GPS-3. Last year prevalence of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population
Table GPS-4. Last year prevalence of drug use among young adults (15 to 34 years old) in nationwide surveys among the general population
Table GPS-5. Last month prevalence of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population
Table GPS-6. Last month prevalence of drug use among young adults (15 to 34 years old) in nationwide surveys among the general population
Table GPS-7. Last month prevalence and frequency of use of cannabis among all adults (15 to 64 years old) and young adults (15 to 34 years old) in nationwide surveys among the general population
Table GPS-7 part (i) Last month prevalence (percentage)
Table GPS-7 part (ii) Frequency of use among all users in last month (percentage)
Table GPS-8 part (i) Lifetime prevalence all adults (percentage): last survey available for each Member State
Table GPS-8 part (ii) Survey methods: last survey available for each Member State
Table GPS-9. Lifetime prevalence (percentage) of drug use among young adults (15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
Table GPS-10. Last year prevalence (percentage) of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population: last survey available for each Member State
Table GPS-11. Last year prevalence (percentage) of drug use among young adults (15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
Table GPS-12. Last month prevalence (percentage) of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population: last survey available for each Member State
Table GPS-13. Last month prevalence (percentage) of drug use among young adults (15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
Table GPS-14. Lifetime prevalence of drug use among youngest adults (15 to 24 years old) in nationwide surveys among the general population
Table GPS-15. Last year prevalence of drug use among youngest adults (15 to 24 years old) in nationwide surveys among the general population
Table GPS-16. Last month prevalence of drug use among youngest adults (15 to 24 years old) in nationwide surveys among the general population
Table GPS-17. Lifetime prevalence of drug use among youngest adults (15 to 24 years old) in nationwide surveys among the general population: last survey available for each Member State
Table GPS-18. Last year prevalence of drug use among youngest adults (15 to 24 years old) in nationwide surveys among the general population: last survey available for each Member State
Table GPS-19. Last month prevalence of drug use among youngest adults (15 to 24 years old) in nationwide surveys among the general population: last survey available for each Member State
Table GPS-20 (Excel format). Methodological information for nation-wide surveys among the general population
Studies of youth and the schools population (EYE) tables
Table EYE-0. School Surveys: sources
Table EYE-1. Recent school surveys: lifetime prevalence (percentage) of psychoactive substance use among students 15 to 16 years old
Table EYE-2. Recent school surveys: prevalence of cannabis use among students 15 to 16 years old
Table EYE-2 part (i). Percent lifetime prevalence (LTP), last year prevalence (LYP), and last month prevalence (LMP)
Table EYE-2 part (ii). Use patterns (percentage)
Table EYE-3. Recent school surveys: lifetime prevalence (LTP) of psychoactive substance use and last month prevalence (LMP) of cannabis (percentage), among students 17 to 18 years old
Table EYE-4 (Excel format). School surveys: lifetime prevalence of psychoactive substance use among students aged 15 to 16 years old
Table EYE-5 School surveys: prevalence of cannabis use among students 15 to 16 years
Table EYE-5 part (i) (Excel format). Prevalence (percentage) for: lifetime (LTP), last year (LYP), and last month (LMP) by gender
Table EYE-5 part (ii) (Excel format). Patterns of use (percentage of overall sample)
Studies of the problematic drug use population (PDU) tables
Table PDU-0. Prevalence of problem drug use at national and sub-national level: bibliographic references
Table PDU-1 part (i). Problem drug use, 2000 to 2004
Table PDU-1 part (ii). Injecting drug use, 1999 to 2003
Table PDU-2. Prevalence of problem drug use at national level: trends
Table PDU-2 part (i) (Excel format). Trends in rates
Table PDU-2 part (ii) (Excel format). Trends in numbers of problem drug users
Table PDU-3. Prevalence of problem drug use at national level: full listing of studies
Table PDU-3 part (i) (Excel format). Problem drug use
Table PDU-3 part (ii) (Excel format). Injecting drug use
Table PDU-4. Prevalence of problem drug use at sub-national level: full list of studies
Table PDU-4 part (i) (Excel format). Problem drug users
Table PDU-4 part (ii) (Excel format). Injecting drug users
Table PDU-5. Prevalence of problem and injecting drug use at sub-national level: trends
Table PDU-5 part (i) (Excel format). Trends in rates per 1000 of the adult population
Table PDU-5 part (ii) (Excel format). Trends in numbers of problem and injecting drug users in the adult population
Studies of drug users in prison (DUP) tables
Table DUP-0. Prevalence of drug use among prisoners: sources and bibliographic references
Table DUP-1. Prevalence of lifetime drug use among prisoners, 1995 to 2004
Table DUP-2. Prevalence of lifetime injecting drug use among prisoners, 1995 to 2004
Table DUP-3. Prevalence of drug use within prison among prisoners, 1995 to 2004
Table DUP-4. Prevalence of injecting drug use within prison among prisoners, 1995 to 2004
Table DUP-5 (Excel format). Prevalence (percentage) of drug use among prisoners in EU Member States, candidate countries and Norway: full listing of studies
Drug related infectious diseases (INF) tables
Table INF-0. Bibliographic references
Table INF-0 part (i). Prevalence data
Table INF-0 part (ii). Notifications data
Table INF-1. Prevalence of HIV infection among injecting drug users in the EU: summary table by country
Table INF-2. Prevalence of HCV antibody among injecting drug users in the EU: summary table by country
Table INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU: summary table by country
Table INF-4 (Excel format). HIV infections newly diagnosed in injecting drug users, by year of report from 1992 to 2004, (a) cases per million population and (b) number of cases
Table INF-5. Notified cases of hepatitis C infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs among all cases with known risk factor
Table INF-5 part (i) (Excel format). Notifications of hepatitis C related to IDU, 1992 to 2004
Table INF-5 part (ii) (Excel format). Notes and comments, 1992 to 2004
Table INF-6. Notified cases of hepatitis B infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs among all notified cases with known risk factor
Table INF-6 part (i) (Excel format). Notifications hepatitis B related to IDU, 1992 to 2004
Table INF-6 part (ii) (Excel format). Notes and comments, 1992 to 2004
Table INF-7. Incidence studies of hepatitis C virus infection among injecting drug users in the EU
Table INF-8. Prevalence of HIV infection (percentage) among injecting drug users
Table INF-8 part (i) (Excel format). HIV prevalence in IDUs: data, 1991 to 2004
Table INF-8 part (ii) (Excel format). HIV prevalence in IDUs: notes, 1991 to 2004
Table INF-9. Prevalence of HIV infection (percentage) among injecting drug users under age 25
Table INF-9 part (i) (Excel format). HIV prevalence young IDUs: data, 1991 to 2004
Table INF-9 part (ii) (Excel format). HIV prevalence young IDUs: notes, 1991 to 2004
Table INF-10. Prevalence of HIV infection (percentage) among new injecting drug users (injecting less than 2 years)
Table INF-10 part (i) (Excel format). HIV prevalence new IDUs: data, 1991 to 2004
Table INF-10 part (ii) (Excel format). HIV prevalence new IDUs: notes, 1991 to 2004
Table INF-11. Prevalence of hepatitis C infection (percentage) among injecting drug users
Table INF-11 part (i) (Excel format). HCV prevalence in IDUs: data, 1991 to 2004
Table INF-11 part (ii) (Excel format). HCV prevalence in IDUs: notes, 1991 to 2004
Table INF-12. Prevalence of hepatitis C infection (percentage) among injecting drug users under age 25
Table INF-12 part (i) (Excel format). HCV prevalence young IDUs: data, 1991 to 2004
Table INF-12 part (ii) (Excel format). HCV prevalence young IDUs: notes, 1991 to 2004
Table INF-13. Prevalence of hepatitis C infection (percentage) among new injecting drug users (injecting less than 2 years)
Table INF-13 part (i) (Excel format). HCV prevalence new IDUs: data, 1991 to 2004
Table INF-13 part (ii) (Excel format). HCV prevalence new IDUs: notes, 1991 to 2004
Table INF-14 part (i) (Excel format). HBsAg prevalence in IDUs: data, 1991 to 2004
Table INF-14 part (ii) (Excel format). HBsAg prevalence in IDUs: notes, 1991 to 2004
Table INF-15. Prevalence of antibodies against hepatitis B virus (percentage) among injecting drug users
Table INF-15 part (i) (Excel format). HBV antibody prevalence in IDUs: data, 1991 to 2004
Table INF-15 part (ii) (Excel format). HBV antibody prevalence in IDUs: notes, 1991 to 2004
Drug-related deaths (DRD) tables
Table DRD-0. Drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions, sources and bibliographic references
Table DRD-1 part (i). 2004 or last year with available information (demographic characteristics)
Table DRD-1 part (ii). 2004 or last year with available information (toxicology and numbers by selected age groups)
Table DRD-1 part (iii). 1990 or closest year with available information
Table DRD-2 part (i). Total drug-related deaths, 1985 to 2004
Table DRD-2 part (ii). Male drug-related deaths, 1990 to 2004
Table DRD-2 part (iii). Female drug-related deaths, 1990 to 2004
Table DRD-2 part (iv). Total drug-related deaths under the age of 25 years old, 1990 to 2004
Table DRD-2 part (v). Totals and indexes, 1985 to 2004
Table DRD-3. Number of acute drug-related deaths recorded in EU Member States, Norway and candidate countries according to EMCDDA standard definition 'Selection B', 1990 to 2004
Table DRD-4. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to EMCDDA standard definition 'Selection D', 1990 to 2004
Table DRD-5. Mortality due to drug-related deaths in European countries, in all adults and adults aged 15 to 39 years (total and males), 2004 or last year with available information
Table DRD-5 part (i). Population mortality rates
Table DRD-5 part (ii). Proportional mortality due to drug-related deaths
Table DRD-6 (Excel format). Methodological features of drug-related deaths reported by National Reitox focal points (based on national definitions - Reitox standard table 5 part 1)
Drug law offences (DLO) tables
Table DLO-1 Number of reports for drug law offences, 1995 to 2004
Table DLO-1 part (i).1995 to 2004
Table DLO-1 part (ii).1985 to 2004
Table DLO-2. Offence types involved in reports for drug law offences: percentage of all reports for drug law offences
Table DLO-3. Drug types involved in reports for drug law offences: percentage of all reports for drug law offences
Table DLO-4. Number of drug law offences related to drug use or possession for use, 1996 to 2004
Table DLO-5. Percentage of total drug law offences that are related to drug use or possession for use, 1996 to 2004
Table DLO-6. Cannabis-related offences: percentage of drug law offences, 1996 to 2004
Table DLO-7. Heroin-related offences: percentage of drug law offences, 1996 to 2004
Table DLO-8. Cocaine-related offences: percentage of drug law offences, 1996 to 2004
Demand for treatment for drug use (TDI) tables
Table TDI-1. Data sources for data on clients entering treatment in 2004
Table TDI-2 part (i). Total numbers of new clients entering treatment
Table TDI-2 part (ii). Total numbers of all clients entering treatment
Table TDI-2 part (iii). Numbers of treatment units covered for reporting clients entering treatment
Table TDI-2 part (iv). Types of units covered for reporting clients entering treatment
Table TDI-3. Distribution by primary drug used of new clients entering treatment, 1993 to 2004
Table TDI-3 part (i). Percent of new clients using heroin
Table TDI-3 part (ii). Percent of new clients using cocaine
Table TDI-3 part (iii). Percent of new clients using cannabis
Table TDI-3 part (iv). Percent of new clients using stimulants (amphetamines and MDMA)
Table TDI-4 part (i). Demographics and injecting status
Table TDI-4 part (ii). Primary drug type used (percent of new clients using) and of those, the percent injecting it
Table TDI-5 part (i). Demographics and injecting status of all clients entering treatment
Table TDI-5 part (ii). Primary drug type used by clients (percent of all clients) and of those, the percent injecting it
Table TDI-5 part (iii). Demographics and injecting status of all men entering treatment
Table TDI-5 part (iv). Demographics and injecting status of all women entering treatment
Table TDI-5 part (v). Primary drug type used by male clients (percent of all male clients)
Table TDI-5 part (vi). Primary drug type used by female clients (percent of all female clients)
Table TDI-6. Trends in gender distribution among new clients entering treatment from 1992 to 2004 (expressed as males / females ratio)
Table TDI-7. Incidence of treatment demands for drug use: new clients entering treatment in 2004 (rate per 100 000 population in 2005)
Table TDI-8. Number of cases covered by the treatment demand indicator schedule reports: new clients and all clients entering treatment in 2004, by type of treatment centre
Table TDI-9. Clients entering outpatient treatment: mean age and gender distribution among new and all clients in 2004
Table TDI-10 part (i). Summary of age distribution (row percentage) for each primary drug type
Table TDI-10 part (ii). Distribution of primary drug used (column percentage) in each age group
Table TDI-10 part (iii). Number of clients using opioids as primary drug
Table TDI-10 part (iv). Number of clients using cocaine (CIH and 'crack') as primary drug
Table TDI-10 part (v). Number of clients using other stimulants as primary drug
Table TDI-10 part (vi). Number of clients using hallucinogens as primary drug
Table TDI-10 part (vii). Number of clients using hypnotics and sedatives as primary drug
Table TDI-10 part (viii). Number of clients using volatile inhalants as primary drug
Table TDI-10 part (ix). Number of clients using cannabis as primary drug
Table TDI-10 part (x). Number of clients using other drugs as primary drugs
Table TDI-11 part (i). Summary of distribution of age at first use (row percentage) for each primary drug type
Table TDI-11 part (ii). Summary of distribution of primary drug used (column percentages) in each age group
Table TDI-11 part (iii). Number of clients using opiates as primary drug
Table TDI-11 part (iv). Number of clients using cocaine as primary drug
Table TDI-11 part (v). Number of clients using stimulants as primary drug
Table TDI-11 part (vi). Number of clients using hypnotics and sedatives as primary drug
Table TDI-11 part (vii). Number of clients using hallucinogens as primary drug
Table TDI-11 part (viii). Number of clients using volatile inhalants as primary drug
Table TDI-11 part (ix). Number of clients using cannabis as primary drug
Table TDI-11 part (x). Number of clients using other drugs as primary drugs
Table TDI-12. New clients entering outpatient treatment: distribution of educational level (percentage) in 2004 for countries reporting data
Table TDI-13. New clients entering outpatient treatment: distribution (percentage) of labour status in 2004 for countries supplying data
Table TDI-14. New clients entering outpatient treatment: distribution (percentage) by accomodation arrangements (persons with whom the client is living) in 2004, for countries submitting data
Table TDI-15. New clients entering outpatient treatment: living conditions in 2004 for countries supplying data
Table TDI-16. New clients entering outpatient treatment: distribution (percent) by source of referral in 2004 for countries supplying data
Table TDI-17 Route of administration of primary drug among new out-patient clients in 2004
Table TDI-17 part (i). Percentage among clients with opioids as primary drug
Table TDI-17 part (ii). Percentage among clients with cocaine as primary drug
Table TDI-17 part (iii). Percentage among clients with stimulants as primary drug
Table TDI-17 part (iv). Percentage among clients with hypnotics and sedatives as primary drug
Table TDI-18. Frequency of use of primary drug among new out-patient clients in 2004
Table TDI-18 part (i). Percentage distribution among clients with opioids as primary drug
Table TDI-18 part (ii). Percentage distribution among clients with cannabis as primary drug
Table TDI-19 New and all clients entering outpatient treatment: distribution by primary drug at treatment in 2004 for those countries supplying data
Table TDI-19 part (i). New clients
Table TDI-19 part (ii). All clients
Table TDI-20. Unemployment rates among new clients entering outpatient treatment in 2004 for countries providing data and in the general population aged 15 to 64 years in 2005
Table TDI-21 part (i). Among new clients entering outpatient treatment
Table TDI-21 part (ii). Among all clients entering outpatient treatment
Table TDI-22. New clients entering outpatient treatment for primary use of amphetamines, ecstasy and other stimulants in 2004 for countries supplying data
Table TDI-23. New clients entering outpatient treatment: distribution of secondary drug used at treatment in 2004: average for those EU countries supplying data
Table TDI-24 part (i). Most frequent combination of the primary drug with the stated types of secondary drug (percentage)
Table TDI-24 part (ii). All clients with opioids as primary drug: numbers reporting the stated drug as secondary
Table TDI-24 part (iii). All clients with cocaine as primary drug type: numbers reporting the stated drugs as secondary
Table TDI-24 part (iv). All clients with cannabis as primary drug: numbers reporting the stated drug as secondary
Table TDI-24 part (v). All clients with stimulants other than cocaine as primary drug type: numbers reporting the stated drugs as secondary
Table TDI-25. All clients entering outpatient and inpatient treatment centres by main drug for which they ask for treatment for those countries supplying data in 2004
Table TDI-26. All clients entering outpatient treatment for opioids by type of opioid misused for countries supplying data in 2004
Table TDI-27. New clients entering outpatient treatment for primary use of cocaine CIH and crack in 2004 for countries supplying data
Table TDI-28. Mean age of new outpatient clients in 2004 by gender and by main drug: overall EU averages for countries reporting data
Table TDI-29. Source of referral among new clients entering outpatient treaatment: overall distribution (percent) by gender for EU countries that supplied data in 2004
Table TDI-30. Mean age at first use among new outpatient clients in 2004 by gender and by main drug: overall EU averages for countries supplying data
Table TDI-31. Gender ratio (ratio of males to females) among all clients entering treatment in 2004 for countries providing data and among drug related deaths in 2004 or most recent year available
Table TDI-32. Gender ratio (ratio of males to females) among all clients entering outpatient treatment by educational level in 2004 for countries reporting data
Table TDI-33 part (i). Summary of EU ratios for countries supplying data
Table TDI-33 part (ii). Opiates
Table TDI-33 part (iii). Cocaine
Table TDI-33 part (iv). Stimulants
Table TDI-34 part (i). EU summary for all drugs
Table TDI-34 part (ii). Opiates
Table TDI-34 part (iii). Cocaine
Table TDI-34 part (iv). Stimulants
Table TDI-34 part (v). Hypnotics and sedatives
Table TDI-34 part (vi). Hallucinogens
Table TDI-34 part (vii). Volatile inhalants
Table TDI-34 part (viii). Cannabis
Table TDI-35. Gender ratio (ratio of males to females) among new outpatient clients by secondary drug most used by country in 2004
Table TDI-36. Gender ratio (ratio of males to females) among all clients entering outpatient treatment by labour status in 2004 for countries reporting data
Table TDI-37. Gender ratio (ratio of males to females) among all clients entering outpatient treatment by living status in 2004 for countries reporting data
Table TDI-38. Gender ratio (ratio of males to females) among all clients entering outpatient treatment by categories of persons with whom they are living for countries reporting data, 2004
Table TDI-40. Unemployment rates among all males and females outpatient clients by country in 2004
Table TDI-41 part (i). Gender ratio (ratio of males to females) among new clients
Table TDI-41 part (ii). Gender ratio (ratio of males to females) among all clients
Table TDI-42 part (i). New clients
Table TDI-42 part (ii). All clients
Methadone substitution and needle and syringe programmes (NSP) tables
Table NSP-0. References for Needle and syringe programme information
Table NSP-1. Number of syringe provision outlets and number of syringes (in thousands) exchanged, distributed or sold 2003
Table NSP-2.Year of introduction of needle and syringe programmes: types of programmes available in 2003
Table NSP-3. Number of non-pharmacy-NSP points (i) and number of syringes exchanged, distributed or sold in 2002 and 2003
Table NSP-4. Total number of pharmacy-based NSPs and number of syringes exchanged or distributed in 2002 and 2003
Table NSP-5. Number of syringe vending machines and number of syringes distributed or sold in 2002 and 2003
Table NSP-6. Number of syringes sold to IDUs at community pharmacies
Table NSP-7. Number of clients in methadone treatment 2003 and 2004
Table NSP-8. Year of introduction of methadone maintenance treatment (MMT), high-dosage buprenorphine treatment (HDBT) and heroin-assisted treatment, including trials
Table NSP-9. Consumption of methadone (kg) in thirty European countries, in the Unites States of America and total consumption worldwide, 1995 to 2004
Drug availability and drug markets: seizures data (SZR) tables
Table SZR-1. Number of cannabis resin seizures, 1995 to 2004
Table SZR-2. Quantities (kg) of cannabis resin seized, 1995 to 2004
Table SZR-3. Number of herbal cannabis seizures, 1995 to 2004
Table SZR-4. Quantities (kg) of herbal cannabis seized, 1995 to 2004
Table SZR-5. Number of seizures of cannabis plants, 1995 to 2004
Table SZR-6. Quantities (number of plants) of cannabis plants seized, 1995 to 2004
Table SZR-7. Number of heroin seizures
Table SZR-7 part (i). 1995 to 2004
Table SZR-7 part (ii). 1985 to 2004
Table SZR-8. Quantities of heroin seized (kgs)
Table SZR-8 part (i). 1995 to 2004
Table SZR-8 part (ii). 1985 to 2004
Table SZR-9. Number of cocaine seizures
Table SZR-9 part (i). 1995 to 2004
Table SZR-9 part (ii). 1985 to 2004
Table SZR-10. Quantities of cocaine seized (kgs)
Table SZR-10 part (i). 1995 to 2004
Table SZR-10 part (ii). 1985 to 2004
Table SZR-11. Number of amphetamine seizures
Table SZR-11 part (i). 1995 to 2004
Table SZR-11 part (ii). 1985 to 2004
Table SZR-12. Quantities of amphetamine seized (kgs)
Table SZR-12 part (i). 1995 to 2004
Table SZR-12 part (ii). 1985 to 2004
Table SZR-13. Number of ecstasy seizures
Table SZR-13 part (i). 1995 to 2004
Table SZR-13 part (ii). 1987 to 2004
Table SZR-14. Quantities of ecstasy seized (tablets)
Table SZR-14 part (i). 1995 to 2004
Table SZR-14 part (ii). 1987 to 2004
Table SZR-15. Number of LSD seizures
Table SZR-15 part (i). 1995 to 2004
Table SZR-15 part (ii). 1985 to 2004
Table SZR-16. Quantities of LSD seized (doses)
Table SZR-16 part (i). 1995 to 2004
Table SZR-16 part (ii). 1985 to 2004
Drug availability and drug markets: prices and purity information (PPP) tables
Table PPP-1. Price of cannabis products at retail level, 2004
Table PPP-1 part (i). Minimum, maximum and average price in Euros
Table PPP-1 part (ii). Sources of information
Table PPP-2. Price of heroin at retail level, 2004
Table PPP-2 part (i). Minimum, maximum and average price in Euros
Table PPP-2 part (ii). Sources of information
Table PPP-3. Price of cocaine at retail level, 2004
Table PPP-3 part (i). Minimum, maximum and average price in Euros
Table PPP-3 part (ii). Sources of information
Table PPP-4. Price of synthetic drugs at retail level, 2004
Table PPP-4 part (i). Minimum, maximum and average price in Euros
Table PPP-4 part (ii). Sources of information
Table PPP-5. Potency of cannabis products at retail level, 2004
Table PPP-5 part (i). Minimum, maximum and average potency measured as percentage of THC content.
Table PPP-5 part (ii). Sources of information
Table PPP-5 part (iii). Sampling frame/type of study
Table PPP-6. Purity of heroin at retail level, 2004
Table PPP-6 part (i). Minimum, maximum and average purity (percentage)
Table PPP-6 part (ii). Sources of information
Table PPP-6 part (iii). Sampling frame/type of study
Table PPP-7. Purity of cocaine products at retail level, 2004
Table PPP-7 part (i). Minimum, maximum and average purity (percentage)
Table PPP-7 part (ii). Sources of information
Table PPP-7 part (iii). Sampling frame/type of study
Table PPP-8. Purity of synthetic drugs at retail level, 2004
Table PPP-8 part (i). Minimum, maximum and average purity (percentage)
Table PPP-8 part (ii). Sources of information
Table PPP-8 part (iii). Sampling frame / Type of study
General population survey (GPS) figures
Figure GPS-1. Proportion of all adults (15 to 64 years old) using cannabis daily or almost daily among current users (used in the last 30 days)
Figure GPS-2. Recent use (last year) of cannabis among young adults, 15 to 34 and 15 to 24 year age groups, measured by population surveys
Figure GPS-3. Current use (last month) of cannabis among youngest adults (aged 15 to 24), measured by national surveys
Figure GPS-4. Trends in recent use (last year prevalence) of cannabis among young adults (aged 15 to 34), measured by national surveys
Figure GPS-5. Recent use (last year) of amphetamines among young adults, 15 to 34 and 15 to 24, measured by population surveys
Figure GPS-6. Trends in recent use (last year) of amphetamines among young adults (aged 15 to 34), measured by population surveys
Figure GPS-7. Lifetime prevalence and recent (last year) use of ecstasy among young adults at selected ages, 15 to 34 and 15 to 24, measured by population surveys
Figure GPS-8. Trends in recent use (last year) of ecstasy among young adults (aged 15 to 34), measured by population surveys
Figure GPS-9. Recent use (last year) of cocaine among all young adults and young males (15 to 34 y), measured by national surveys
Figure GPS-10. Trends in recent use (last year prevalence) of cocaine among young adults (aged 15 to 34), measured by population surveys
Figure GPS-11. Lifetime prevalence of cannabis among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 year age group, measured by population surveys
Figure GPS-12. Last year prevalence of cannabis among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 year age group, measured by national population surveys
Figure GPS-13. Current use (last 30 days) of cannabis among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 year age group
Figure GPS-14. Trends in recent use (last year) of cannabis among younger adults (aged 15 to 24), measured by national surveys
Figure GPS-15. Lifetime prevalence of amphetamine use among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 year age group
Figure GPS-16. Last year prevalence of amphetamines among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 year age group, in some EU countries
Figure GPS-17. Trends in recent use (last year prevalence) of amphetamines among younger adults (aged 15 to 24) as measured by national surveys
Figure GPS-18. Lifetime prevalence of ecstasy among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 year age group
Figure GPS-19. Last year prevalence of ecstasy among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 year age group
Figure GPS-20. Trends in recent use (last year prevalence) of ecstasy among younger adults aged 15 to 24 as measured by national surveys
Figure GPS-21. Lifetime prevalence of cocaine use among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 year age group, in some EU countries
Figure GPS-22. Last year prevalence of cocaine use among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 year age group, in some EU countries
Figure GPS-23. Recent use (last year) of amphetamines, ecstasy and cocaine among young adults
Figure GPS-23 part (i). Last year use among the 15 to 34 year age group
Figure GPS-23 part (ii). Last year use among the 15 to 24 year age group
Figure GPS-24. Continuation rates of cannabis (last year and last month use among lifetime users) in the general population, as measured by national surveys
Figure GPS-25. Recent use (last year) of cannabis by age group in United Kingdom, measured by national population surveys
Figure GPS-26. Trends in current use (last 30 days) of cannabis among young adults (aged 15 to 34) in some EU Member States and Norway, as measured by national population surveys
Figure GPS-27. Recent use (last year) of cannabis by age group in some Member States and candidate countries, measured by national population surveys: last survey available
Figure GPS-27 part (i). Last year prevalence in some of the EU-15 Member States
Figure GPS-27 part (ii). Last year prevalence in some new EU Member States and candidate countries
Figure GPS-28. Continuation rates of cocaine (last year and last month use among lifetime users) in the general population, as measured by national surveys
Figure GPS-29. Continuation rates of ecstasy (last year and last month use among lifetime users) in the general population, as measured by national surveys
Figure GPS-30. Trends in recent amphetamines, ecstasy and cocaine use (last 12 months prevalence) among young adults (15 to 34 years old) in England and Wales
Figure GPS-31. Last year prevalence of amphetamine use (last survey available) in young adults (15 to 34 years old)
Figure GPS-32. Last year prevalence of ecstasy use (last survey available) among young adults (15 to 34 years old)
Figure GPS-33. Overview of drug prevalence estimates from various studies in Europe for all adults (15 to 64 yrs old) and young adults (15 to 34 yrs old).
Figure GPS-33 part (i). Cannabis use: lifetime experience, recent use (last 12 months) and current use (last 30 days).
Figure GPS-33 part (ii). Cocaine, amphetamine and ecstasy use: lifetime experience, recent use (last 12 months) and current use (last 30 days)
Figure GPS-34. Comparison of drug use prevalence during last year by different user groups in the general population aged 15 to 34: data for Spain, 1999.
Studies of youth and the schools population (EYE) figures
Figure EYE 1. Cannabis prevalence rates among school students in 1995, 1999 and 2003
Figure EYE 1 part (i). Comparison of two age groups (15/16 and 17/18 years old) for lifetime use of cannabis (%)
Figure EYE-1 part (ii). Lifetime prevalence (percentage) of cannabis use among 15/16 year old school students in 1995, 1999 and 2003
Figure EYE-2. Lifetime prevalence for drugs other than cannabis among 15/16 year old students
Figure EYE-2 part (i). Changes 1995 to 2003 in lifetime prevalence (percentage) of ecstasy use
Figure EYE-2 part (ii). Lifetime prevalence for use of ecstasy and amphetamines (percentage) in 2003
Studies of the problematic drug use population (PDU) figures
Figure PDU-1. Estimates of the prevalence of problem drug use (rate per 1000 population aged 15 to 64), 2000 to 2004
Figure PDU-1 part (i). All estimates
Figure PDU-1 part (ii). All estimates combined
Figure PDU-1 part (iii). Estimates for opioids and stimulants
Figure PDU-2. Estimates of the prevalence of injecting drug use (rate per 1000 population aged 15 to 64), 2000 to 2004
Figure PDU-2 part (i). Overall prevalence
Figure PDU-2 part (ii). Opioids use prevalence
Figure PDU-3. Trends in injecting drug use - percentage current injecting among heroin clients entering treatment, 1994 to 2004
Figure PDU-3 part (i). Percentage among all clients with heroin as primary drug
Figure PDU-3 part (ii). Percentage among clients with heroin as primary drug entering treatment for the first time
Figure PDU-4. Estimated trends in the prevalence of problem drug use 1995 to 2004 (rate per 1000 population aged 15 to 64)
Figure PDU-4 part (i). Combined estimates per country (overall prevalence)
Figure PDU-4 part (ii). Combined estimates per country (opioids use prevalence)
Figure PDU-5. Estimated trends in the prevalence of injecting drug use, 1995 to 2004 (rate per 1000 population aged 15 to 64)
Figure PDU-6. National and sub-national estimates of the prevalence of problem drug use (rate per 1000 population aged 15 to 64), 2000 to 2004
Figure PDU-6 part (i). Overall prevalence
Figure PDU-6 part (ii). Opioids use prevalence
Figure PDU-7. National and sub-national estimates of the prevalence of injecting drug use, 2000 to 2004 (rate per 1000 population aged 15 to 64)
Studies of drug users in prison (DUP) figures
Figure DUP-1. Studies of lifetime prevalence of use of various drugs among prisoners, 1999 to 2004 in some EU countries
Drug related infectious diseases (INF) figures
Figure INF-1. AIDS incidence by year of diagnosis adjusted for reporting delays
Figure INF-1 part (i). Incidence among injecting drug users by country, 1995 to 2004
Figure INF-1 part (ii). Incidence by transmission group: summary for EU countries, 1995 to 2004
Figure INF-2. HIV infections newly diagnosed in injecting drug users by year of report 1995 to 2004, cases per million population
Figure INF-2 part (i). EU countries, candidate countries and Norway
Figure INF-2 part (ii). Estonia, Latvia, Lithuania, Portugal, Russian Federation and Ukraine
Figure INF-2 part (iii). EU, candidate countries and Norway, excluding Estonia, Latvia, Lithuania and Portugal
Figure INF-3 part (i). All injecting drug users, 2003 to 2004
Figure INF-3 part (ii). Young injecting drug users (under age 25), 2003 to 2004
Figure INF-3 part (iii). All injecting drug users by gender, age, years of injecting and primary drug (where data available), 2000 to 2004
Figure INF-3 part (iv). All injecting drug users: Map of EU, 2003 to 2004
Figure INF-3 part (v). All injecting drug users, by gender (where data available), 2003 to 2004
Figure INF-4 part (i). All injecting drug users
Figure INF-4 part (ii). Young injecting drug users (under age 25)
Figure INF-4 part (iii). National and sub-national samples of new IDUs (injecting less than 2 years), 1995 to 2004
Figure INF-5. Estimated HIV prevalence among injecting drug users: selected country-specific studies
Figure INF-5 part (i). Italy: prevalence among users in drug treatment and prisons: by region. 2000 to 2004
Figure INF-5 part (ii). France: prevalence among users in 12 cities by gender, age and opioids use. 2001 to 2003
Figure INF-5 part (iii). Luxembourg: prevalence among users in contact with drug services, by gender and age. 1996 to 2004
Figure INF-5 part (iv). UK (England and Wales): prevalence among users in contact with drug services, by gender, age and injecting history
Figure INF-5 part (v). Austria: prevalence among drug-related deaths (injecting drug users) by gender, age and opioid-relatedness. 1995 to 2004
Figure INF-5 part (vi). Spain: prevalence among injecting drug users in drug treatment, by gender, age, injecting history, opioids use and first treatment demand. 1996 to 2002
Figure INF-6 part (i). All injecting drug users, 2003 to 2004
Figure INF-6 part (ii). Young injecting drug users (under age 25), 2003 to 2004
Figure INF-6 part (iii). New injecting drug users (injecting less than 2 years), 2003 to 2004
Figure INF-6 part (iv). All injecting drug users - Map of EU, 2003 to 2004
Figure INF-6 part (v). All injecting drug users by gender, age, years of injecting and primary drug (where data is available)
Figure INF-7 part (i). All injecting drug users
Figure INF-7 part (ii). Young injecting drug users (under age 25)
Figure INF-7 part (iii). New injecting drug users (injecting less than 2 years)
Figure INF-8 part (i). Proportion injecting drug users among all cases with risk factor information, 2000 to 2004
Figure INF-8 part (ii). Indexed trend in numbers of injecting drug users, 1995 to 2004
Figure INF-9 part (i). Percentage RNA positive and percentage HCV antibody positive injecting drug users
Figure INF-9 part (ii). Percentage RNA positive and HCV antibody positive in samples of injecting drug users
Figure INF-9 part (iii). Percentage distribution of HCV genotypes (G1 to G4) in samples of injecting drug users
Figure INF-10. Prevalence of markers of HBV infection estimated among national and sub-national samples of injecting drug users 2003 to 2004, where data are available
Figure INF-10 part (i). Percentage positive for ever infected (aHBc) and current infection (HBsAg)
Figure INF-10 part (ii). Percentage positive for aHBc (ever infected): map of EU
Figure INF-10 part (iii). Percentage positive for HBsAg (current infection); map of EU
Figure INF-11. Trends in prevalence of markers of HBV infection estimated from national and sub-national samples of injecting drug users 1995 to 2004, where data are available
Figure INF-11 part (i). Injecting drug users aHBc positive (ever infected)
Figure INF-11 part (ii). Injecting drug users HBsAg positive (current infection)
Figure INF-12. Notified cases of hepatitis B in injecting drug users, EU countries where data are available
Figure INF-12 part (i). Proportion injecting drug users among hepatitis B notifications with risk factor information, 2000 to 2004
Figure INF-12 part (ii). Indexed trend for numbers of hepatitis B notifications related to injecting drug use, 1995 to 2004
Figure INF-13. Estimated HIV, HCV and HBV prevalence among injecting drug users: studies with national and sub-national coverage: summary of all available data across EU Member States, candidate countries and Norway, 2000 to 2004
Figure INF-14. Newly diagnosed HIV infections and HAART coverage in the WHO European region
Figure INF-14 part (i). HIV cases under age 25 as percentage of all HIV cases
Figure INF-14 part (ii). IDU as percentage of all HIV cases
Figure INF-14 part (iii). HAART coverage by 3/2003
Figure INF-14 part (iv). HAART coverage by 1/2006
Drug-related deaths (DRD) figures
Figure DRD-1. Proportion of acute drug-related deaths that show presence of opiates in the period 2002 to 2004
Figure DRD-2. Proportion of acute drug-related deaths occurring under the age of 25 years in 2002
Figure DRD-3. Trends in mean age of acute drug-related deaths in some of the EU-15 Member States, 1990 to 2004
Figure DRD-4. Trends in mean age of acute drug-related deaths in some new Member States and candidate countries of the EU 1990 to 2003/04
Figure DRD-5. lndexed trends in acute drug-related deaths and in the numbers of deaths under 25 years old
Figure DRD-5 part (i). Indexed trend in the EU-15 Member States and Norway 1990 to 2004
Figure DRD-5 part (ii). Indexed trend in the new Member States 1990 to 2004
Figure DRD-6. Indexed overall trends for males and females in acute drug-related deaths in the EU-15 Member States and Norway, 1990 to 2004
Figure DRD-7. Indexed time series of acute drug-related deaths in different countries and in the EU as a whole
Figure DRD-7 part (i). Index in some Member States, 1985 to 2004
Figure DRD-7 part (ii). Index in some Member States, 1985 to 2004
Figure DRD-8. Indexed long term trend in acute drug-related deaths in the EU, 1985 to 2004
Figure DRD-9. Trends in the proportion of drug-related deaths occurring under the age of 25 years old in the Member States and candidate countries 1990 to 2004 (three year moving average)
Figure DRD-9 part (i). Some Member States, 1990 to 2004
Figure DRD-9 part (ii). Some Member States, 1990 to 2004
Figure DRD-10. Mean age of acute drug-related deaths by gender, last year with available data
Drug law offences (DLO) figures
Figure DLO-1. Drug law offences in EU Member States, candidate countries and Norway, 1999 to 2004
Figure DLO-1 part (i). Drug law offences in EU-15 Member States and Norway, 1999 to 2004: Indexes (100 = mean 1999 to 2004)
Figure DLO-1 part (ii). Drug law offences in new EU Member States and candidate countries, 1999 to 2004: Indexes (100 = mean 1999 to 2004)
Figure DLO-2 part (i). Cannabis-related offences in new EU Member States and candidate countries, 1999 to 2004: Indexes (100 = mean 1999 to 2004)
Figure DLO-2 part (ii). Cannabis-related offences in new EU Member States and candidate countries, 1999 to 2004: Indexes (100 = mean 1999 to 2004)
Figure DLO-3 part (i). EU-15 Member States and Norway, 1999 to 2004
Figure DLO-3 part (ii). New EU Member States and candidate countries, 1999 to 2004
Figure DLO-4 part (i). Cocaine-related offences in EU-15 Member States and Norway, 1999 to 2004: Indexes (100 = mean 1999 to 2004)
Figure DLO-4 part (ii). Cocaine-related offences in new EU Member States and candidate countries, 1999 to 2004: Indexes (100 = mean 1999 to 2004)
Figure DLO-5. Heroin-related offences in EU Member States and candidate countries, 1999 to 2004
Figure DLO-5 part (i). Heroin-related offences in EU-15 Member States, 1999 to 2004: Indexes (100 = mean 1999 to 2004)
Figure DLO-5 part (ii). Heroin-related offences in new EU Member States and candidate countries, 1999 to 2004 - Indexes (100 = mean 1999 to 2004)
Demand for treatment for drug use (TDI) figures
Figure TDI-1 part (i). Distribution (percentage) of new clients per drug (heroin, cannabis, cocaine, other stimulants)
Figure TDI-1 part (ii). Numbers of new clients per drug (heroin, cannabis, cocaine, other stimulants)
Figure TDI-2 part (i). New clients
Figure TDI-2 part (ii). All clients
Figure TDI-3. Trend in coverage of treatment demand data from 1999 to 2004: number of new clients, all clients and numbers of treatment units
Figure TDI-4. Unemployment rates among new clients entering outpatient treatment in 2004 and in the general population aged 15 to 74 for countries providing data
Figure TDI-5. Proportion of all outpatient treatment clients with unstable accommodation, in some European countries in 2004
Figure TDI-6. Age distribution by primary drug among new clients in outpatient treatment centres: summary for those countries supplying data for 2004
Figure TDI-7. Male to female ratio for new outpatient clients by primary drug type (opiates, cocaine and stimulants) compared with those injecting the drug: summary for those European countries supplying data for 2004
Figure TDI-8. Male to female ratio by primary drug among new outpatient clients compared with daily users of the drug summary for those European countries supplying data for 2004
Figure TDI-9. Male to female ratio among all clients entering treatment in 2004 and among known drug related deaths in 2004 or most recent year available
Figure TDI-10. Male to female ratio for all outpatient clients living with their children and those living without children, in countries reporting data for 2004
Methadone substitution and needle and syringe programmes (NSP) figures
Figure NSP-1. Year of introduction of MMT and HDBT in 27 European countries
Figure NSP-2. Methadone consumption in the US and in EU-25, 1999 to 2004 according to INCB
Figure NSP-3. Priority for and extent of use of selected measures to prevent infectious diseases in drug users, according to national expert opinion: summary for responding countries
Figure NSP-4. Extent of use of five selected response strategies to reduce drug-related deaths in 27 countries
Drug availability and drug markets: prices and purity information (PPP) figures
Figure PPP-1. Average potency of cannabis resin at retail level measured as percentage of THC content, 1999 to 2004
Figure PPP-2. Average potency of herbal cannabis at retail level measured as percentage of THC content, 1999 to 2004
Figure PPP-3. Indexed trends in EU retail prices for major drug types, adjusting for inflation, 1999 to 2004